
11 Jan 2019 Research
Myelofibrosis: Finding new ways to treat patients
Myelofibrosis is a fatal bone marrow cancer. The disease is caused by excessive secretion of factors by cancerous platelet-producing cells called megakaryocytes. These secretions cause the replacement of normal bone marrow tissue with fibrous scar tissue.
Dr Chen’s team can successfully recreate this pathological bone marrow environment in the laboratory, and their preliminary research data shows that reduced levels of a protein complex called FANCcore leads to more myelofibrosis.
Dr Chen’s team hypothesise that loss of the protein complex FANCcore increases the growth of myelfibrosis by altering megakaryocytes. Dr Chen uses both human tissue cultures and mouse models to examine the cellular and molecular changes to megakaryocytes following the absence of the FANCcore complex and to understand how these changes cause myelofibrosis.
The team hopes that by focusing on the role of FANCcore in megakaryocyte biology, they can reveal new ways to treat myelofibrosis.
Related posts
4 April 2022
Leukaemia UK launches search for five new talented Trustees
We are looking for a talented and diverse set of Trustees to join our Board, and help guide the charity as we embark on an ambitious new strategy to accelerate progress in leukaemia research to stop leukaemia devastating lives.
11 January 2019
Lymphoma: Understanding relapse and treatment resistance
Dr Dinis Calado, The Francis Crick Institute and Project Grant Holder
26 October 2021
Leukaemia UK announced as one of five charities for star-studded event Shall We Dance? with Dame Arlene Phillips and Anton Du Beke
Leukaemia UK is delighted to have been announced as one of five charities for whom the proceeds of a new star-studded dance event, Shall We Dance?, will go towards when it takes place next year.
14 March 2023
Percy & Nell says Pants to Leukaemia with bespoke charity collaboration
Independent clothing brand Percy & Nell has produced a unique range of sweatshirts, t-shirts, beanies and tote bags, with all profits going to Leukaemia UK. The collaboration comes off the…